$32 million new equity injection adds to previously announced $59 million New investors Tencent and BGF joined by all existing major shareholders Funds will advance pipeline of novel TCR-CD3 bispecifics in cancer and autoimmune disease 13 November 2025; Cambridge, England – T-Therapeutics, a…
Read More
Theodora has over 25 years’ experience in the biotech sector, with a proven track record of dynamic leadership. 10 March 2025; Cambridge, England – T-Therapeutics, a biotechnology company developing next-generation soluble T cell receptor (TCR) therapeutics targeting cancer and autoimmune indications, announces the…
Read More
Industry veteran, founder of Medivation and serial entrepreneur joins T-Therapeutics to support development of the company’s pipeline of TCR-based immuno-oncology drugs 12 June 2024; Cambridge, England – T-Therapeutics, a biotechnology company developing next-generation soluble TCR therapeutics targeting cancer and autoimmune indications, today announces…
Read More
Fundraise led by Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital with participation from Sanofi Ventures and the University of Cambridge Venture Fund Unique transgenic mouse platform harnesses natural power of T cells to build a portfolio of first-in-class cancer medicines…
Read More
